We are live on ! Find out more
SLRN

ACELYRIN

Delisted

SLRN was delisted on the 21st of May, 2025.

110 hedge funds and large institutions have $639M invested in ACELYRIN in 2023 Q4 according to their latest regulatory filings, with 35 funds opening new positions, 31 increasing their positions, 28 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

866% more call options, than puts

Call options by funds: $4.96M | Put options by funds: $513K

46% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 24

11% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 28

9% more funds holding

Funds holding: 101110 (+9)

1.84% more ownership

Funds ownership: 86.18%88.02% (+1.8%)

14% less funds holding in top 10

Funds holding in top 10: 76 (-1)

25% less capital invested

Capital invested by funds: $847M → $639M (-$208M)

Holders
110
Holders Change
+9
Holders Change %
+8.91%
% of All Funds
1.6%
Holding in Top 10
6
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-14.29%
% of All Funds
0.09%
New
35
Increased
31
Reduced
28
Closed
24
Calls
$4.96M
Puts
$513K
Net Calls
+$4.45M
Net Calls Change
+$6.94M
Name Holding Trade Value Shares
Change
Change in
Stake
ACMC
1
AyurMaya Capital Management Company
New Hampshire
$69.6M
Fidelity Investments
2
Fidelity Investments
Massachusetts
$65.8M -$1.19M -139,455 -2%
Citadel Advisors
3
Citadel Advisors
Florida
$48.3M +$4.67M +547,355 +9%
Vanguard Group
4
Vanguard Group
Pennsylvania
$45.9M +$25.3M +2,966,883 +93%
OM
5
Opaleye Management
Massachusetts
$30.9M
O
6
OrbiMed
New York
$29.9M -$11.3M -1,324,591 -25%
VP
7
venBio Partners
California
$28.7M
JP Morgan Chase
8
JP Morgan Chase
New York
$23.8M +$208K +24,386 +0.8%
AG
9
Artal Group
Luxembourg
$22.6M +$4.84M +566,609 +23%
BlackRock
10
BlackRock
New York
$21.7M +$6.05M +709,436 +32%
TCM
11
Tybourne Capital Management
Hong Kong
$21.7M +$5.77M +676,187 +30%
GA
12
General Atlantic
New York
$21.6M
SB
13
Samsara BioCapital
California
$18.8M +$1.21M +141,443 +6%
BOCH
14
Blue Owl Capital Holdings
New York
$17.1M +$19.6M +2,292,990 New
IC
15
Ikarian Capital
Texas
$14.9M -$7.92M -927,421 -32%
Morgan Stanley
16
Morgan Stanley
New York
$13.2M +$12.9M +1,513,865 +607%
Janus Henderson Group
17
Janus Henderson Group
United Kingdom
$12M -$1.64M -192,537 -11%
DC
18
Decheng Capital
California
$10.2M +$11.7M +1,370,951 New
LGM
19
Logos Global Management
California
$9.32M +$10.7M +1,250,000 New
KCM
20
Kynam Capital Management
New Jersey
$8.95M
Goldman Sachs
21
Goldman Sachs
New York
$8.35M -$5.64M -660,914 -37%
RI
22
RTW Investments
New York
$7.3M
WP
23
Woodline Partners
California
$7.08M +$347K +40,646 +4%
VA
24
VR Adviser
New York
$6.99M +$621K +72,781 +8%
Marshall Wace
25
Marshall Wace
United Kingdom
$6.67M

SLRN Hedge Fund Activity: Q4 2023 in Review

110 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in ACELYRIN (SLRN) for Q4 2023, worth a combined $639M — down 25% from $847M a quarter earlier.

Buyers outnumbered sellers: 35 funds opened new SLRN positions and 24 closed out — a net gain of 11 holders — while 31 added to existing stakes and 28 trimmed.

The largest buyer was Vanguard Group, adding an estimated $25.3M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $14.3M sold.

  • 110 institutional investors held ACELYRIN (SLRN) as of Q4 2023, up from 101 in Q3 2023.
  • Funds reported $639M of ACELYRIN stock for Q4 2023, down 25% quarter-over-quarter.
  • 35 funds opened new ACELYRIN positions in Q4 2023 and 24 closed out, a net change of +11 holders.
  • The largest ACELYRIN buyer in Q4 2023 was Vanguard Group, an estimated $25.3M added.
  • The largest ACELYRIN seller in Q4 2023 was EcoR1 Capital, an estimated $14.3M sold.

Based on aggregated 13F filings for Q4 2023.